Table III.

Reactivity of CTLs from HLA-B27–positive Subjects towards the pVIPR Peptide in the Context of Either B*2705 or B*2709 Molecules

DonoraNumber
 of CTLsSpecific lysis of
 T2-B*2709 > 05bSpecific lysis of
 T2-B*2709 = 05cSpecific lysis of
 T2-B*2709 < 05bSpecific lysis of T2-B*2705 only
MP199730
EP60411 (EP76)
AS41300
AB20200
MD41210
LV21010
CV20200
Total3912 (30.7%)20 (51.3%)6 (15.4%)1 (2.6%)
  • a Five donors (MP, EP, AS, AB, and MD) are HLA-B*2705–positive patients with AS. LV is an HLA-B*2702–positive patient with AS, and CV is a healthy HLA-B*2705–positive individual. The results summarize the data obtained in two cytotoxicity experiments. Background (specific lysis of unpulsed T2-B*2705 and T2-B*2709) was <12%.

  • b The difference in the percentage of specific lysis between T2-B*2705 and T2-B*2709 cells after background subtraction was >20%.

  • c The difference in the percentage of specific lysis between T2-B*2705 and T2-B*2709 cells after background subtraction was <20%.